Improving Symptoms, Function, and Weight Loss in HFpEF Patients with Obesity Heart Matters
-
- Ciencias
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Javed Butler, MD, MBA, MPH
There’s no approved therapies specifically targeting obesity and HFpEF, but based on the STEP-HFpEF study that was presented at the 2023 ESC Congress, the treatment option semaglutide improves heart failure-related symptoms, physical function, and weight loss among patients with HFpEF and obesity. Here to walk through the study’s key findings with Dr. Mary Katherine Cheeley is fellow ReachMD host, Dr. Javed Butler, President of Baylor Scott and White Research Institute in Dallas, Texas.
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Javed Butler, MD, MBA, MPH
There’s no approved therapies specifically targeting obesity and HFpEF, but based on the STEP-HFpEF study that was presented at the 2023 ESC Congress, the treatment option semaglutide improves heart failure-related symptoms, physical function, and weight loss among patients with HFpEF and obesity. Here to walk through the study’s key findings with Dr. Mary Katherine Cheeley is fellow ReachMD host, Dr. Javed Butler, President of Baylor Scott and White Research Institute in Dallas, Texas.